Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
Shareholders’ aggregate participation is capped at $50 million and depends on a qualifying voucher being awarded and monetized.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Atossa Therapeutics (ATOS) executed a contingent value rights agreement giving shareholders contractual participation in potential priority review voucher proceeds. The board declared one contingent value right (CVR) per common share outstanding at the close of business on October 19, 2026. Shares issued afterward also carry one CVR until detachment or agreement expiration.
Holders are entitled collectively to 25% of net proceeds from sale or deemed monetization of the first qualifying FDA priority review voucher (PRV), capped at $50 million. The voucher must be awarded by December 31, 2036, unless the board extends the date. CVRs remain attached to shares unless the board detaches them. Atossa has rare pediatric disease designations for (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome, but has submitted no marketing application for either indication and has received no PRV.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointExecuted definitive CVR agreement gives holders contractual participation in potential voucher value.
- Minor point. Forward-looking: it has not happened yet and may not happen.Dividend grants one CVR per share on October 19, 2026; subsequent shares qualify until detachment or expiration.
- Minor point. Forward-looking: it has not happened yet and may not happen.CVR holders receive collectively 25% of net proceeds from the first qualifying PRV’s sale or deemed monetization.
- Minor point. Forward-looking: it has not happened yet and may not happen.Own use or change of control with an unsold qualifying PRV triggers deemed monetization at independently determined fair value.
- Minor point(Z)-endoxifen received FDA Rare Pediatric Disease Designation for Duchenne muscular dystrophy and McCune-Albright syndrome.
Negative
- Moderate pointDMD and MAS programs have no submitted marketing applications; Atossa has received no PRV.
- Minor pointAggregate CVR payments are capped at $50 million.
- Minor pointPRV eligibility depends on FDA approval of a qualifying marketing application and applicable statutory and regulatory requirements.
- Minor point. Forward-looking: it has not happened yet and may not happen.Qualifying vouchers must be awarded by December 31, 2036, unless the board extends that date.
- Minor pointCVRs permit no separate transfers or trading while attached to common shares.
- Minor pointCVR agreement imposes no obligation to conduct studies, pursue approvals or monetize a voucher.
News Explained
The agreement defines company use or certain change-of-control events as monetization, but does not oblige Atossa to pursue or sell a qualifying voucher.
Under the executed agreement, CVRs stay with their corresponding Atossa shares unless the board detaches them; while attached, holders cannot trade them separately.
If Atossa uses a qualifying voucher for its own application, or a change of control occurs while it holds an unsold qualifying voucher, the agreement treats the event as a deemed monetization, valued by an independent financial advisor.
The agreement does not require Atossa to conduct a particular clinical study, pursue or obtain regulatory approval or designation, or sell or otherwise monetize a voucher.
Details
Market Reaction – ATOS
On Oct 9, the day this news came out, the latest delayed price for ATOS is 0.32% above the previous close. Argus tracked a peak move of +5.8% during the session. Our momentum scanner has recorded 9 alerts for this stock so far that day. The latest delayed price is $2.43. Relative volume is exceptionally heavy at 26.6x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Participation in net proceeds
- 25%
- Aggregate holder share from monetization of the first qualifying PRV
- Aggregate payment cap
- $50 million
- Maximum total payments under the CVR Agreement
- CVRs per share
- 1 CVR per share
- Shares outstanding on the record date and qualifying shares issued afterward
- Record date
- October 19, 2026
- Outstanding shares eligible for the CVR dividend
- Outside date
- December 31, 2036
- Deadline for the first qualifying PRV, subject to possible board extension
Historical Context
-
Earlier plan set the same 25% proceeds share and $50 million cap; this agreement formalizes it.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
contingent value rights financial
priority review voucher regulatory
cusip technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter
CVRs entitle holders to
In connection with the execution of the CVR Agreement, Atossa's Board of Directors declared a dividend of one stapled CVR for each share of Atossa common stock outstanding at the close of business on October 19, 2026, the record date. Each share of Atossa common stock issued after the record date and prior to any detachment of the CVRs or expiration of the CVR Agreement will also carry one CVR.
The CVRs provide shareholders with a contractual right to participate in the potential future value of the first qualifying FDA priority review voucher ("PRV") awarded to Atossa. Under the CVR Agreement, holders will be entitled, in the aggregate, to
"With the execution of the CVR Agreement, we have converted the commitment we announced in September into a contractual right for our shareholders," said Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer. "If our development programs ultimately result in a qualifying priority review voucher, our shareholders will have a direct opportunity to participate in a meaningful portion of that potential value. At the same time, the structure preserves Atossa's flexibility to make development and capital allocation decisions that we believe are in the best interests of the Company and its shareholders."
Atossa has received FDA Rare Pediatric Disease Designation for (Z)-endoxifen for the treatment of Duchenne muscular dystrophy ("DMD") and McCune-Albright syndrome ("MAS"). If the FDA approves a qualifying marketing application for either program, or another qualifying Atossa development program, the Company may be awarded a PRV, subject to the applicable statutory and regulatory requirements.
No Atossa product candidate has been approved by the FDA for any indication, Atossa has not submitted a marketing application for (Z)-endoxifen for DMD or MAS, and no PRV has been awarded to the Company. Receipt of a Rare Pediatric Disease Designation does not itself result in the award of a PRV, and there can be no assurance that Atossa will receive or monetize a PRV or that any payment will ultimately be made under the CVRs.
Key Terms of the CVR Agreement
- One CVR per share. Each share of Atossa common stock outstanding as of the close of business on October 19, 2026 will receive one CVR. Shares issued after the record date and prior to any detachment or expiration of the CVRs will also carry one CVR.
25% participation. CVR holders will be entitled, in the aggregate, to25% of the net proceeds from the sale or deemed monetization of Atossa's first qualifying PRV.$50 million $50 million - Stapled to ATOS shares. Unless and until the Board elects to detach the CVRs, each CVR will remain attached to its corresponding share of Atossa common stock and may be transferred only together with that share. The CVRs will not separately trade or have a separate CUSIP while attached.
- Company use of a voucher. If Atossa uses a qualifying PRV for its own application, or a change of control occurs while Atossa holds an unsold qualifying PRV, the event will be treated as a deemed monetization based on fair market value determined by an independent financial advisor.
- Outside date. The CVRs apply to the first qualifying PRV awarded on or before December 31, 2036, subject to the Board's ability to extend that date under the CVR Agreement.
The CVR Agreement does not require Atossa to conduct any particular clinical study, pursue or obtain any regulatory approval or designation, or sell or otherwise monetize a PRV. Atossa retains discretion over its development, regulatory and commercial strategy, including whether and when to sell, use or retain any PRV it may receive.
The CVR Agreement will be filed with the
About Atossa Therapeutics
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company's lead product candidate, (Z)-endoxifen, is in development across several clinical settings, including potential applications in oncology and rare diseases. Atossa has received FDA Orphan Drug Designation for (Z)-endoxifen for Duchenne muscular dystrophy and Rare Pediatric Disease designations for Duchenne muscular dystrophy and McCune-Albright syndrome. (Z)-endoxifen is not approved for any indication. More information is available at atossatherapeutics.com.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of applicable securities laws, including but not limited to, the Company's potential eligibility for, award of a Rare Pediatric Disease priority review voucher, the potential value and monetization of a qualifying voucher, the issuance and operation of the CVRs; the development, regulatory prospects and potential approval of Atossa's product candidates; and the possibility, amount and timing of any CVR payment. Words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "design," "predict," "future," or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; FDA approval of a qualifying product candidate and the award of a voucher; changes to or expiration of the applicable voucher program; the risk that any voucher's value, permitted deductions, number of outstanding CVRs and ability or timing to make a payment may differ materially from current expectations; and other risks and uncertainties detailed from time to time in Atossa's filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Any CVR payment is subject to the CVR agreement, including its payment cap and provisions concerning legally permitted distributions and solvency.
The market value of a priority review voucher is variable and subject to a number of factors beyond our control and reported past priority review voucher sale amounts are not necessarily indicative of priority review voucher sale amounts in the future.
Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-executes-contingent-value-rights-agreement-providing-shareholders-participation-in-potential-priority-review-voucher-value-302902776.html
SOURCE Atossa Therapeutics Inc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What happens to Atossa CVRs if the company uses its priority review voucher?
Atossa’s use of a qualifying voucher for its own application counts as deemed monetization, based on fair market value determined by an independent financial advisor. The same treatment applies if a change of control occurs while Atossa holds an unsold qualifying voucher.
Does Atossa’s CVR agreement require the company to develop a drug or sell a voucher?
The agreement does not require Atossa to conduct any particular clinical study, pursue or obtain regulatory approval or designation, or sell or otherwise monetize a voucher. Atossa retains discretion over its development, regulatory and commercial strategy, including whether and when to sell, use or retain a voucher.